Overview: NGS Inclusion Myopathy Sequencing TestIntroduction: The NGS Inclusion Myopathy Sequencing Test sequences genes to diagnose inclusion myopathy, causing muscle weakness. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected inclusion body myopathy.
Other Names: Inclusion Myopathy NGS Assay, GNE Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Inclusion myopathy sequencing began in the 2000s with myopathy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose inclusion myopathy, guides treatment, and evaluates patients with muscle weakness.
Test Parameters: 1. Inclusion Myopathy Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of muscle weakness, myalgia, or inclusion myopathy symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document muscle weakness, myalgia, distal weakness, or family history of inclusion myopathy. Include current medications, especially immunosuppressive therapies.
Consent: Written consent required, detailing the tests purpose, inclusion myopathy implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze inclusion myopathy genes (e.g., GNE). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for inclusion myopathy diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm inclusion myopathy, guiding supportive care or genetic counseling. Negative results may require muscle biopsy.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Muscle biopsy, EMG, or creatine kinase levels to confirm inclusion myopathy diagnosis.
Test Limitations: Not all inclusion myopathy cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Myopathy Guidelines, 2023; Neurology, Argov Z, 2022.
